HAL (France)
open access
Esketamine for Treatment-Resistant Depression
To the Editor Janik et al reported a positive trial of esketamine monotherapy for treatment-resistant depression. However, the lead-in design and functional unblinding could have biased treatment estimates. The 4-week double-blind phase was preceded by a lead-in phase of up to 7 weeks, during which
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Predictors of Esketamine Response in Treatment-Resistant Depression: The Role of Temperament and Cumulative Treatment Resistance#644193
- Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study.#140786
- Esketamine on Postpartum Depression in Cesarean Section Women#868319
- Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation#1243300
- Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.#9993
Record · ID 1367073
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive